A SPAC III Acquisition Corp. filings document the regulatory record of a British Virgin Islands blank-check company with Nasdaq-listed units, Class A ordinary shares and rights. Its disclosures cover 8-K material events, proxy and governance matters, shareholder votes, capital-structure changes, sponsor share arrangements and SPAC security terms.
The filing record includes amendments to the company’s memorandum and articles of association, business-combination deadline-extension matters, unregistered equity issuance disclosure, PFIC annual statement materials and exhibits related to formal corporate actions.
W. R. Berkley Corporation and Berkley Insurance Company report no current ownership of A SPAC III ACQUISITION CORP. Class A ordinary shares. The amended Schedule 13G/A states they beneficially own 0 shares, representing 0.0% of the class, with the reportable event dated 12/31/2025. The filing confirms they hold no voting or dispositive power over these securities and that their holdings are 5 percent or less of the class.
A SPAC III Acquisition Corp’s major associated investors report no ownership of its Class A ordinary shares. ATW SPAC Management LLC, Kerry Propper and Antonio Ruiz-Gimenez each report beneficial ownership of 0 shares, or 0.0% of the class, as of 12/31/2025.
They also report no sole or shared voting or dispositive power over any shares and state they now own 5 percent or less of the class. The signatories certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
A SPAC III Acquisition Corp. entered into an exchange agreement with its sponsor under which the sponsor transferred 1,499,900 Class B ordinary shares to the company in exchange for 1,499,900 newly issued Class A ordinary shares. These new Class A shares carry the same restrictions that applied to the Class B shares, including transfer limits, waiver of redemption rights and an obligation to vote in favor of an initial business combination as described in the IPO prospectus. After this share exchange, the company has 2,337,481 Class A shares and 100 Class B shares outstanding, and the sponsor holds approximately 76.4% of the outstanding Class A shares. The 1,499,900 Class A shares were issued as unregistered equity securities in reliance on the exemption in Section 3(a)(9) of the Securities Act of 1933.
A SPAC III Acquisition Corp. filed its 10-Q, reporting Q3 results and key developments. The company recorded net income of $480,352, driven by interest income of $654,307 on trust investments, offset by general and administrative expenses of $173,955. The trust account held $62,268,671 as of September 30, 2025.
After quarter-end, shareholders redeemed 5,717,419 Class A shares for $59,502,057, leaving about $2.9 million in the trust. Following these redemptions, the Sponsor held approximately 76.4% of 2,337,581 outstanding ordinary shares. The company’s charter extension gives it until November 12, 2026 to complete a merger.
The company signed a merger agreement with Bioserica for total consideration of $217,860,000 in newly issued PubCo shares, subject to customary conditions. Management disclosed substantial doubt about its ability to continue as a going concern if no business combination is completed within the permitted period.
A SPAC III Acquisition Corp. (ASPC) amended its charter to extend the deadline to complete a business combination by 12 months, moving from November 12, 2025 to November 12, 2026, effective October 27, 2025.
Shareholders approved the charter amendment at an extraordinary general meeting on October 27, 2025. Votes cast were 4,178,733 FOR and 2,934,951 AGAINST. As of the October 6, 2025 record date, 8,055,000 ordinary shares were outstanding, and 7,113,684 shares were voted, representing 88.31% of outstanding shares.
An aggregate of 5,717,419 ordinary shares were tendered for redemption in connection with the meeting. Separately, on October 25, 2025, the Sponsor agreed to transfer 100,000 Class B ordinary shares after the consummation of an initial business combination to an unaffiliated third party in exchange for that party voting 621,084 Class A ordinary shares in favor of the amendment.
ASPC seeks shareholder approval to amend its charter to extend the deadline to complete an initial business combination from November 12, 2025 to November 12, 2026. The Board has unanimously approved a proposed merger with Bioserica International Limited that would (i) reincorporate the company through a merger with a Purchaser and (ii) make Bioserica a wholly-owned subsidiary of the surviving entity. Public shareholders may elect cash redemption based on the Trust Account balance; an illustrative per-share redemption price was approximately $10.38 as of October 6, 2025. The Sponsor owns 1,500,000 Founder Shares and 285,000 Private Placement Units; if no combination occurs by the Extended Termination Date those holdings would become worthless. The Sponsor currently does not plan to contribute additional funds to the Trust Account. The proposal does not add funds to the Trust Account; approval would give the company more time to complete the Business Combination but may reduce per-share trust proceeds available to redeeming public shareholders.
The preliminary proxy describes a proposed Charter Amendment to extend ASPC's combination deadline from November 12, 2025 to November 12, 2026 and related shareholder votes. It discloses a May 23, 2025 Merger Agreement to combine with Bioserica via a series of reincorporation and acquisition mergers, which the board unanimously approved and will be submitted to shareholders for separate approval. Public shareholders may redeem for a cash amount equal to the trust account balance (less up to $100,000 for dissolution expenses) divided by outstanding public shares; if the company winds up, rights to receive post-combination ordinary shares will expire worthless. The proxy notes the Sponsor does not currently intend to fund an extension, officers and insiders may not be reimbursed for excess out-of-pocket expenses if no combination occurs, founder/private placement shares remain locked until a business combination, and national security (CFIUS) and other regulatory risks may limit target availability.